
Avadel Pharma (AVDL) Stock Forecast & Price Target
Avadel Pharma (AVDL) Analyst Ratings
Bulls say
Avadel Pharmaceuticals PLC demonstrates a positive financial outlook driven by the anticipated growth of its product LUMRYZ, which may surpass $500 million in peak sales due to its convenient once-nightly dosing compared to existing treatments. The company has achieved cash flow positivity attributable to robust LUMRYZ sales since its approval in 2023, alongside strong patient adoption, with over 3,100 patients reported using the drug as of June 30. Furthermore, ongoing developments, including the pivotal trial for the idiopathic hypersomnia indication, are expected to yield favorable data, potentially expanding Avadel's market presence and offering additional growth opportunities.
Bears say
Avadel Pharmaceuticals faces significant challenges that contribute to a negative outlook on its stock. Key risks include the potential for slower-than-expected market uptake of LUMRYZ due to anticipated generic competition, pricing pressures, and the uncertainty surrounding ongoing patent litigation, which may hinder effective commercialization efforts. Additionally, the failure of the Phase 3 trial for idiopathic hypersomnia and setbacks associated with other drug candidates pose considerable clinical and financial hurdles for the company.
This aggregate rating is based on analysts' research of Avadel Pharma and is not a guaranteed prediction by Public.com or investment advice.
Avadel Pharma (AVDL) Analyst Forecast & Price Prediction
Start investing in Avadel Pharma (AVDL)
Order type
Buy in
Order amount
Est. shares
0 shares